All In Biotech

Drug Trial Radar · NCT05769868

Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

Prospective, Multicenter and Open Study to Evaluate the Efficacy of Esmolol in the Early Identification of Cardiovascular Disorders Induced by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

Last checked: Nov 19, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Apr 18, 2023

Primary completion

Mar 2027

Study completion Sep 2027

Sponsor

Sponsor type
Government (non-federal)
Collaborators
Instituto de Salud Carlos III
First posted
Mar 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.

Conditions

  • Cirrhosis
  • Diabetes Mellitus
  • Oncologic Disorders

Interventions

  • Esmolol Injection [Brevibloc]Drug

    Brevibloc® will be administered intravenously by infusion pump following the administration schedule: Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes. If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute. The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg. The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Left Ventricle (LV) ejection fractionTime frame: At Baseline (Day 1) until Month-24 according to cohort
  2. Peak measurement of global LV systolic longitudinal strainTime frame: At Baseline (Day 1) until Month-24 according to cohort
  3. Ejection Intraventricular Pressure Difference (EIVPD) measureTime frame: At Baseline (Day 1) until Month-24 according to cohort

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona, Spain · Not yet recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain · Recruiting

  • Hospital Clínico Universitario de Salamanca

    Salamanca, Salamanca, Spain · Recruiting

  • Hospital Universitari i Politècnic La Fe

    Valencia, Valencia, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.